Open AccessIn Vitro Activity and In Vivo Efficacy of Posaconazole in Treatment of Murine Infections by Different Isolates of the Aspergillus terreus Complex
Author(s) -
Valentina Salas,
Francisco Pastor,
M. Mar Rodríguez,
Enrique Calvo,
Emilio Mayayo,
Josep Guarro
Publication year - 2011
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00736-10
Subject(s) - posaconazole , aspergillus terreus , galactomannan , aspergillosis , in vivo , broth microdilution , microbiology and biotechnology , aspergillus , biology , in vitro , pharmacology , antifungal , amphotericin b , immunology , antibiotics , minimum inhibitory concentration , biochemistry
Posaconazole (PSC) is an antifungal drug recommended as an alternative for the treatment of invasive aspergillosis in patients who are refractory or intolerant to primary antifungal therapy. We have evaluated thein vitro activity of PSC against 21 strains of theAspergillus terreus complex using both broth microdilution and disk diffusion (Neo Sensitabs) methods. PSC showed the same high level of activity against all the strains with the twoin vitro methods used. We developed a murine model of disseminated infection to evaluate the efficacy of PSC at 5, 10, or 20 mg/kg of body weight twice a day by using 6 different strains chosen randomly. PSC showed good efficacy, especially at 20 mg/kg, as measured by prolonged survival, tissue burden reduction, histopathology, and lowered galactomannan levels. The PSC levels in serum on the fourth day of treatment were higher than the MICs for the strains tested.